2.06 USD
-0.16 (-7.21%)
2.09 USD
+0.03 (+1.46%)
We assign a fundamental rating of 2 out of 10 to VVOS. VVOS was compared to 101 industry peers in the Health Care Providers & Services industry. VVOS may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, VVOS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
VVOS had negative earnings in the past year.
VVOS had a negative operating cash flow in the past year.
In the past 5 years VVOS always reported negative net income.
VVOS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VVOS has a worse Return On Assets (-66.70%) than 89.11% of its industry peers.
With a Return On Equity value of -675.51%, VVOS is not doing good in the industry: 80.20% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.7% | ||
| ROE | -675.51% | ||
| ROIC | N/A |
ROA(3y)-124.43%
ROA(5y)-96.22%
ROE(3y)-1313.92%
ROE(5y)-818.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 55.74%, VVOS is doing good in the industry, outperforming 79.21% of the companies in the same industry.
VVOS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for VVOS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.74% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7%
GM growth 5Y-4.62%
2. Health
2.1 Basic Checks
VVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VVOS has been increased compared to 1 year ago.
The number of shares outstanding for VVOS has been increased compared to 5 years ago.
There is no outstanding debt for VVOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VVOS has an Altman-Z score of -7.45. This is a bad value and indicates that VVOS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.45, VVOS is doing worse than 89.11% of the companies in the same industry.
A Debt/Equity ratio of 3.36 is on the high side and indicates that VVOS has dependencies on debt financing.
VVOS has a worse Debt to Equity ratio (3.36) than 76.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.36 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.45 |
ROIC/WACCN/A
WACC8.98%
2.3 Liquidity
A Current Ratio of 0.78 indicates that VVOS may have some problems paying its short term obligations.
VVOS has a worse Current ratio (0.78) than 84.16% of its industry peers.
A Quick Ratio of 0.78 indicates that VVOS may have some problems paying its short term obligations.
VVOS has a worse Quick ratio (0.78) than 77.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
VVOS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.84%, which is quite impressive.
Looking at the last year, VVOS shows a quite strong growth in Revenue. The Revenue has grown by 18.76% in the last year.
The Revenue has been growing slightly by 5.70% on average over the past years.
EPS 1Y (TTM)68.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.5%
Revenue 1Y (TTM)18.76%
Revenue growth 3Y-3.81%
Revenue growth 5Y5.7%
Sales Q2Q%75.73%
3.2 Future
The Earnings Per Share is expected to grow by 27.98% on average over the next years. This is a very strong growth
VVOS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.41% yearly.
EPS Next Y33.4%
EPS Next 2Y27.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year14.35%
Revenue Next 2Y33.41%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VVOS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VVOS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VVOS's earnings are expected to grow with 27.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.98%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for VVOS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.06
-0.16 (-7.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.96%
Inst Owner Change0%
Ins Owners16.39%
Ins Owner Change0%
Market Cap18.52M
Revenue(TTM)17.32M
Net Income(TTM)-17.10M
Analysts80
Price Target5.61 (172.33%)
Short Float %4.28%
Short Ratio2.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.13%
Min EPS beat(2)-40.06%
Max EPS beat(2)5.81%
EPS beat(4)2
Avg EPS beat(4)-3.51%
Min EPS beat(4)-40.06%
Max EPS beat(4)30.5%
EPS beat(8)4
Avg EPS beat(8)-3.42%
EPS beat(12)7
Avg EPS beat(12)6.07%
EPS beat(16)8
Avg EPS beat(16)0.24%
Revenue beat(2)1
Avg Revenue beat(2)18.61%
Min Revenue beat(2)-0.98%
Max Revenue beat(2)38.2%
Revenue beat(4)1
Avg Revenue beat(4)2.79%
Min Revenue beat(4)-19.36%
Max Revenue beat(4)38.2%
Revenue beat(8)2
Avg Revenue beat(8)0.82%
Revenue beat(12)2
Avg Revenue beat(12)-4.63%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.76%
PT rev (3m)4.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.82%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.07 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.77
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS1.93
BVpS0.28
TBVpS-0.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.7% | ||
| ROE | -675.51% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.74% | ||
| FCFM | N/A |
ROA(3y)-124.43%
ROA(5y)-96.22%
ROE(3y)-1313.92%
ROE(5y)-818.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7%
GM growth 5Y-4.62%
F-Score2
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.36 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 97.02% | ||
| Cap/Sales | 5.65% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | -7.45 |
F-Score2
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)121.46%
Cap/Depr(5y)141.96%
Cap/Sales(3y)5.11%
Cap/Sales(5y)6.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.5%
EPS Next Y33.4%
EPS Next 2Y27.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)18.76%
Revenue growth 3Y-3.81%
Revenue growth 5Y5.7%
Sales Q2Q%75.73%
Revenue Next Year14.35%
Revenue Next 2Y33.41%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.97%
OCF growth 3YN/A
OCF growth 5YN/A
VIVOS THERAPEUTICS INC / VVOS FAQ
What is the ChartMill fundamental rating of VIVOS THERAPEUTICS INC (VVOS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VVOS.
Can you provide the valuation status for VIVOS THERAPEUTICS INC?
ChartMill assigns a valuation rating of 1 / 10 to VIVOS THERAPEUTICS INC (VVOS). This can be considered as Overvalued.
How profitable is VIVOS THERAPEUTICS INC (VVOS) stock?
VIVOS THERAPEUTICS INC (VVOS) has a profitability rating of 1 / 10.
Can you provide the financial health for VVOS stock?
The financial health rating of VIVOS THERAPEUTICS INC (VVOS) is 0 / 10.
Can you provide the expected EPS growth for VVOS stock?
The Earnings per Share (EPS) of VIVOS THERAPEUTICS INC (VVOS) is expected to grow by 33.4% in the next year.